357625-50-4
Chemical Structure
TRC4186
- CAS No.: 357625-50-4
- Formula:C13H14ClN3O4S2
- Molecular Weight:375.85
InChIKey: QWXKHFBZAGOZJM-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C[N+](CC(C2=CC=CS2)=O)=C1)NNS(=O)(C)=O.[Cl-]
Biological Activity: TRC4186 is a potent advanced glycation end-product (AGE) breaker. TRC4186 breaks advanced glycation end-products, reduces their tissue accumulation, and decreases AGE burden. TRC4186 improves endothelial and myocardial function, preserves cardiac function, retards renal dysfunction, and reduces renal dysfunction severity. TRC4186 downregulates brain natriuretic peptide and IL-6 expression. TRC4186 can be used for the research of diabetic macro- and microvascular complications, diabetic heart failure, diabetic renal failure, hypertension, diabetes, diabetic cardiomyopathy, and diabetic nephropathy[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TRC4186 | TRC4186 is a potent advanced glycation end-product (AGE) breaker. TRC4186 breaks advanced glycation end-products, reduces their tissue accumulation, and decreases AGE burden. TRC4186 improves endothelial and myocardial function, preserves cardiac function, retards renal dysfunction, and reduces renal dysfunction severity. TRC4186 downregulates brain natriuretic peptide and IL-6 expression. TRC4186 can be used for the research of diabetic macro- and microvascular complications, diabetic heart failure, diabetic renal failure, hypertension, diabetes, diabetic cardiomyopathy, and diabetic nephropathy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chandra KP, Shiwalkar A, Kotecha J, Thakkar P, Srivastava A, Chauthaiwale V, Sharma SK, Cross MR, Dutt C. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects. Clinical drug investigation. 2009 Sep;29(9):559-75. [Content Brief]
- [2]. Rosenthal T, et al. Combating Combination of Hypertension and Diabetes in Different Rat Models. Pharmaceuticals (Basel, Switzerland). 2010 Mar 26;3(4):916-939. [Content Brief]
- [3]. Joshi D, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. Journal of cardiovascular pharmacology. 2009 Jul;54(1):72-81. [Content Brief]
- [4]. Yamagishi S, et al. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders. Rejuvenation research. 2012 Dec;15(6):564-72. [Content Brief]
Keywords
